These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


215 related items for PubMed ID: 39135206

  • 1. Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34+ cells and PD-L1 CAR-modified UCB-CD34+-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells.
    Ghaedrahmati F, Akbari V, Seyedhosseini-Ghaheh H, Esmaeil N.
    Stem Cell Res Ther; 2024 Aug 13; 15(1):257. PubMed ID: 39135206
    [Abstract] [Full Text] [Related]

  • 2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, Lee JH, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW.
    J Immunother Cancer; 2020 May 13; 8(1):. PubMed ID: 32439799
    [Abstract] [Full Text] [Related]

  • 3. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
    Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H.
    PLoS One; 2010 Feb 15; 5(2):e9221. PubMed ID: 20169160
    [Abstract] [Full Text] [Related]

  • 4. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C.
    J Immunother Cancer; 2021 Mar 15; 9(3):. PubMed ID: 33741731
    [Abstract] [Full Text] [Related]

  • 5. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A, Sun Y, Wang S, Du J, Gao X, Yuan Y, Zhao L, Yang Y, Xu L, Lei Y, Duan L, Xu C, Ma L, Wang J, Hu G, Chen H, Wang Q, Hu L, Zhang B.
    Cytotherapy; 2020 Dec 15; 22(12):734-743. PubMed ID: 32684339
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W.
    Clin Cancer Res; 2021 Jan 15; 27(2):473-484. PubMed ID: 33028589
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N.
    Clin Transl Med; 2022 Jun 15; 12(6):e901. PubMed ID: 35696531
    [Abstract] [Full Text] [Related]

  • 10. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M.
    Invest New Drugs; 2021 Feb 15; 39(1):34-51. PubMed ID: 32772342
    [Abstract] [Full Text] [Related]

  • 11. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S, Lacan C, Roos-Weil D.
    Bull Cancer; 2021 Oct 15; 108(10S):S81-S91. PubMed ID: 34920811
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT.
    Cytotherapy; 2023 Feb 15; 25(2):148-161. PubMed ID: 36396553
    [Abstract] [Full Text] [Related]

  • 13. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, Wang R, Zhu L, Meng Y, Hu C, Liang H, Lin X, Zhu K, Chen G, Luo KQ, Di L, Zhao Q.
    J Hematol Oncol; 2021 Jan 29; 14(1):21. PubMed ID: 33514401
    [Abstract] [Full Text] [Related]

  • 14. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
    Andreu-Saumell I, Rodriguez-Garcia A, Mühlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagué J, Brasó-Maristany F, Calderon H, Angelats L, Colell S, Nuding M, Soria-Castellano M, Barbao P, Prat A, Urbano-Ispizua A, Huppa JB, Guedan S.
    Nat Commun; 2024 Apr 26; 15(1):3552. PubMed ID: 38670972
    [Abstract] [Full Text] [Related]

  • 15. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.
    Myers Chen K, Grun D, Gautier B, Venkatesha S, Maddox M, Zhang AH, Andersen P.
    Front Immunol; 2024 Apr 26; 15():1380065. PubMed ID: 38726005
    [Abstract] [Full Text] [Related]

  • 16. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
    Hagihara M, Gansuvd B, Ueda Y, Tsuchiya T, Masui A, Tazume K, Inoue H, Kato S, Hotta T.
    Cancer Immunol Immunother; 2002 Mar 26; 51(1):1-8. PubMed ID: 11845254
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
    Xia W, Chen J, Hou W, Chen J, Xiong Y, Li H, Qi X, Xu H, Xie Z, Li M, Zhang X, Li J.
    Int J Mol Sci; 2023 Apr 06; 24(7):. PubMed ID: 37047817
    [Abstract] [Full Text] [Related]

  • 20. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, Yenchitsomanus PT.
    Biomed Pharmacother; 2023 Dec 06; 168():115691. PubMed ID: 37844355
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.